In today’s episode, Lucas Harrington — co-founder and president of Mammoth Biosciences — joins Eric to discuss a groundbreaking moment for gene editing: the successful treatment of an infant, K.J. Muldoon, using a custom CRISPR therapy developed in just six months. Lucas walks us through how this came together, what made it possible, and why this case could mark the beginning of a new era in personalized medicine.

They also explore the technical and regulatory infrastructure that enabled the treatment, the challenges of in vivo gene editing beyond the liver, and why Lucas believes the brain is the next frontier. As one of the original minds behind Mammoth and a close collaborator of CRISPR pioneer Jennifer Doudna, Lucas brings deep insight into where the field is headed.

We also covered Google’s latest solar deal, Regeneron’s acquisition of 23andMe, AMD’s ZT Systems divestiture, and Grok 3 coming to Azure.